Welcome to our dedicated page for InfuSystem Holdings SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on InfuSystem Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into InfuSystem Holdings's regulatory disclosures and financial reporting.
InfuSystem Holdings reported Q2 2026 net revenues of $36,933 (in thousands), up 2.6% from $36,002 (in thousands), as gross margin increased to 58.0%. Net income for the quarter rose to $3,231 (in thousands), or $0.15 diluted EPS, compared with $2,599 (in thousands), or $0.12. For the first half of 2026, net revenues were $70,617 (in thousands) and net income was $4,248 (in thousands), versus $70,718 and $2,332 (in thousands) a year earlier.
Patient Services revenue grew 15.2% in Q2, driven by higher Oncology volume and 154% growth in Wound Care, including new compression therapy products, while Device Solutions revenue declined 16.1% following a restructured GE Healthcare services contract and a prior-period rental buyout. Total assets were $97,700 (in thousands) with long‑term debt of $20,424 (in thousands) and available liquidity of $55,207 (in thousands). Operating cash flow was $7,747 (in thousands) for the first half, supporting continued investment in medical equipment and IT, and the board authorized a new $20,000 (in thousands) share repurchase program through June 30, 2028.
InfuSystem Holdings, Inc. outlines a home healthcare services platform that shifts complex therapies from hospitals to the home through two revenue engines: Patient Services and Device Solutions. Patient Services generates about 60% of revenue and Device Solutions about 40%, supported by 800+ payer contracts and relationships with 18 of the top 20 U.S. hospital systems.
For 2025, net revenue was $143.4 million, up 6% year over year, with adjusted EBITDA of $31.5 million, up 25%, driving a 21.9% adjusted EBITDA margin and 8.3% operating margin. Wound Care treatment revenue grew 103% in 2025 as a key adjacent therapy, while LTM adjusted EBITDA margin reached 22.4% as of the second quarter of 2026. As of June 30, 2026, equity was $59.1 million, total long-term debt $20.4 million, net leverage 0.61x and total available liquidity $55.2 million, backed by $23.4 million of cash provided by operations. Management targets 6–8% pro forma revenue growth and adjusted EBITDA margins in the low-to-mid 20% range over time.
InfuSystem Holdings, Inc. reported second quarter 2026 net revenues of $36.9 million, up 2.6% from $36.0 million a year earlier, with record revenue driven by strong Patient Services growth. Patient Services revenue rose to $24.8 million, up 15.2%, while Device Solutions revenue declined to $12.1 million, down 16.1%, reflecting a previously restructured GE Healthcare biomedical services contract and lower equipment sales.
Gross profit increased to $21.4 million with gross margin improving to 58.0%, supported by higher Device Solutions margins. Net income was $3.2 million, or $0.15 per diluted share, versus $2.6 million, or $0.12, in 2025. Non-GAAP Adjusted EBITDA rose to $8.6 million, a 7.6% increase, with margin of 23.4%. Liquidity totaled $55.2 million as of June 30, 2026, and net debt was $19.5 million. The company repurchased $3.5 million of stock in the quarter and reaffirmed full-year 2026 guidance for pro-forma net revenue growth of 6%–8% and Adjusted EBITDA margins in the mid to low 20% range.
BlackRock, Inc. reports beneficial ownership of common stock of InfuSystem Holdings, Inc. as of June 30, 2026. BlackRock reports beneficial ownership of 1,286,129 shares of common stock, representing 6.4% of the class.
BlackRock has sole voting power over 1,269,273 shares and sole dispositive power over 1,286,129 shares, with no shared voting or dispositive power. The filing aggregates holdings of certain BlackRock business units. Various underlying clients have rights to dividends and sale proceeds, but no single client reportedly holds more than five percent of InfuSystem’s outstanding common shares.
InfuSystem Holdings, Inc. announced it will release its second quarter 2026 financial results on Tuesday, August 4, 2026 before the market opens. Management will host a conference call for investors the same day at 9:00 a.m. Eastern Time, accessible by telephone and live webcast through the company’s investor relations website. A telephone and web replay will be available through Wednesday, November 4, 2026. InfuSystem describes itself as a leading national health care service provider operating two platforms: Patient Services and Device Solutions.
InfuSystem Holdings Executive VP and CFO Barry G. Steele reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 17, 2026, 21,323 performance-based restricted stock units granted on May 17, 2024 vested and converted into common shares, increasing his holdings.
Across May 16–18, 2026, Steele exercised restricted stock units covering 7,511 and 8,715 shares of common stock and had 3,275, 9,297 and 3,800 shares withheld to satisfy tax liabilities tied to these vestings. Following these transactions, he directly owned 117,767 shares of InfuSystem common stock. Certain remaining restricted stock units are scheduled to vest in two equal annual installments beginning on May 16, 2027.
InfuSystem Holdings EVP-Chief HR Officer Jerod Funke reported compensation-related stock activity involving restricted stock units and associated tax withholding. On May 17, 2026, 14,570 performance-based restricted stock units granted on May 17, 2024 vested and converted into common stock on a one-for-one basis.
To cover tax liabilities from vesting and settlement on May 16–17, 2026, a total of 8,761 shares of common stock were withheld at $8.77 per share, which is reported as a disposition but is not an open-market sale. Funke’s direct common stock holdings increased to 36,116 shares after these transactions, and 10,363 restricted stock units remain outstanding, vesting in two equal annual installments beginning on May 16, 2027.
InfuSystem Holdings President and CEO Carrie Lachance reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 17, 2026, 21,855 performance-based restricted stock units granted on May 17, 2024 vested, converting into common stock on a one-for-one basis. On May 16 and May 18, she exercised restricted stock units covering 10,418 and 8,932 shares of common stock, respectively.
To cover tax liabilities from these vesting and settlement events, the issuer withheld 4,100 shares at $8.77, 5,322 shares at $8.77, and 3,515 shares at $8.90 per share. Following these transactions, Lachance directly holds 266,391 shares of common stock. Footnotes state that certain restricted stock units cliff vested on May 18, 2026, while others vest in two equal annual installments beginning May 17, 2027.
InfuSystem Holdings Executive VP and CIO Addam Chupa reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 16, 2026, 4,375 restricted stock units converted into common stock on a one-for-one basis, with 1,602 shares withheld at $8.77 per share to cover tax liabilities. On May 17, 2026, 12,184 performance-based restricted stock units granted on May 17, 2024 vested, and 4,460 shares were withheld at $8.77 per share for taxes. On May 18, 2026, an additional 5,447 restricted stock units cliff vested and converted into common stock, with 1,994 shares withheld at $8.90 per share for tax obligations. Following these non-market transactions, Chupa directly held 61,160 shares of InfuSystem common stock.
InfuSystem Holdings, Inc. announced that its Board of Directors has approved a new stock repurchase program authorizing the Company to buy back up to $20 million of its outstanding common stock. The program will run from July 1, 2026 through June 30, 2028.
This new authorization will supersede the current repurchase program, which is scheduled to expire on June 30, 2026. Under the current authorization, InfuSystem repurchased approximately 1.6 million shares for about $11.9 million through March 31, 2026, reflecting ongoing use of buybacks as a capital allocation tool.